April 2, 2013 - N30 Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society
March 13, 2013 - N30 Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
October 8, 2012 - N30 Names Sherif Gabriel, Ph.D. as VP Research
August 27, 2012 - N30 Pharma Converts from LLC to C-Corp
February 21, 2012 - Board Adds Evan Loh, MD and John R. Moore

March 21, 2013 - S-nitrosoglutathione Reductase Inhibitors Modulate F508-del CFTR Protein Levels and Chloride Secretion In Vitro
March 20, 2013 - Small Molecule Inhibitors of GSNOR Possess Anti-Inflammatory and Bronchodilatory Actions in Mouse Models of Inflammatory Lung Disease and Modulate CFTR Function in F508del-CFTR Mice
November 11, 2011 - S-Nitrosoglutathione Reductase Inhibitors for the Prevention and Treatment of Experimental Colitis
August 28, 2011 - Structure – Activity Relationships of Pyrrole Based S-Nitrosoglutathione Reductase Inhibitors – Carboxamide Modification
July 14, 2011 - Heterozygous Deletion of S-Nitrosoglutathione Reductase in Mice Does Not Increase Nitrosative Inactivation of O6-Alkylguanine-DNA Alkyltransferase or Diethylnitrosamine-induced Hepatocarcinogenesis

GSNOR Inhibitor Drugs

GSNOR Inhibitor Drugs

N30 Pharma has a broad portfolio of GSNOR inhibitor drug candidates that are potent, long lasting, and can be administered by a variety of routes, including oral, parenteral, inhalation and topical.

Key Chemical Series	Expansion and Optimization	Results
N6 Series	463 compounds	61 compounds <100 nM IC₅₀
N7 Series	245 compounds	112 compounds <100 nM IC₅₀
N9 Series	353 compounds	121 compounds <100 nM IC₅₀

From the portfolio above, N30 Pharma has screened and selected a number of lead drug candidates that are currently in various stages of development.

	Intravenous/Inhalation	Oral
Lead	N6022	N91115/69
Backup	N6547	N91138
Lead Rationale	Low oral bioavailability IC₅₀ 8 – 12 nM Broad therapeutic index Significant anti-inflammatory and bronchoprotective effects	High oral bioavailability IC₅₀ 11-22 nM Tox/ADME results support development Chronic oral dosing Sustained effects ≥ 24hrs
Status	Phase 1 and 2 Clinical Studies	IND enablement

January 24, 2013 - Pharmacological Inhibition of S-Nitrosoglutathione Reductase Improves Endothelial Vasodilatory Function in Rats in vivo
December 28, 2012 - ADH IB Expression, but Not ADH III, Is Decreased in Human Lung Cancer
February 15, 2012 - Mechanism of Inhibition for N6022, a First-in-Class Drug Targeting GSNOR
January 13, 2012 - Structure–activity relationship of pyrrole based GSNOR inhibitors
August 25, 2011 - Preclinical 28-Day Inhalation Toxicity Assessment of S-Nitrosoglutathione
July 26, 2011 - Discovery of potent and novel GSNOR inhibitors devoid of cytochrome P450 activities
April 19, 2011 - Structure–activity relationships of pyrrole based GSNOR inhibitors: Pyrrole regioisomers and propionic acid replacement